CDK4/6 inhibitorPhase 3 trialInvestigational
Kisqali
Generic name: ribociclib
How it works
Blocks the CDK4/6 proteins, which are involved in the growth and division of cancer cells.
Cancer types
Melanoma— All patients
Efficacy
In clinical trials, around 40% of patients achieved an objective response, with a median progression-free survival of approximately 5.6 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating a New Treatment Combination for Advanced Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Ribociclib and Hormone Therapy in Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Assessing the Effectiveness and Safety of Ribociclib in Breast Cancer Treatment | Breast Cancer | preclinical | — | Source → |
| Evaluating Patient Outcomes with Ribociclib in Early-Stage Breast Cancer | Breast Cancer | preclinical | — | Source → |
| CDK4/6 Inhibitors Linked to Cardiotoxic Events in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.